By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Med BioGene has withdrawn its planned initial public offering in the US, the Canadian personalized diagnostics firm said in a document filed with the US Securities and Exchange Commission last week.

In the filing, Med BioGene said it decided not to pursue its IPO "due to the availability of other opportunities" that its board "deemed to be in the best interests of the company and its shareholders." It did not provide further details.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, says.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.